Applied Clinical Trials Direct
Having trouble viewing this e-mail?
Click here
.
October 29, 2012
Website
Blog
Advertise
Subscribe
PRINT SUBSCRIBE
DIGITAL SUBSCRIBE
News Roundup:
EMA to Meet Business Targets
Feature Articles:
FDA Warning Letter Study
Blog Posts:
Implications of Biosimilar Development
EMA On Track to Meet Core Business Targets for 2012
Vivus Wants REMS Amended for Qysmia
Partnership for Expanded Publishing and Submission of Reg Docs
Regulators Must Modify Approach
News from RAPS
FDA Warning Letter Study
Developing Quality Biosimilars
Conflict of Interest at EMA
Implications of Biosimilar Development
Are Cardiovascular Problems Ever Not a Risk?
Lisa Henderson
Editor in Chief
[email protected]
FDA Meeting of the Drug Safety and Risk Management Advisory Committee,
October 29 and 30
CBI's Life Sciences Forum on GCP Compliance and Quality Oversight
CBI's 4
th
Annual Effective Preparation for FDA Advisory Committee Meetings